JP2016538313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538313A5 JP2016538313A5 JP2016535053A JP2016535053A JP2016538313A5 JP 2016538313 A5 JP2016538313 A5 JP 2016538313A5 JP 2016535053 A JP2016535053 A JP 2016535053A JP 2016535053 A JP2016535053 A JP 2016535053A JP 2016538313 A5 JP2016538313 A5 JP 2016538313A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- halogen
- hydrogen
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 130
- 229910052739 hydrogen Inorganic materials 0.000 claims description 120
- 229910052736 halogen Chemical group 0.000 claims description 102
- 239000001257 hydrogen Substances 0.000 claims description 92
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 92
- 150000002367 halogens Chemical group 0.000 claims description 75
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 54
- 125000003545 alkoxy group Chemical group 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 40
- 229910052799 carbon Inorganic materials 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000011780 sodium chloride Substances 0.000 claims description 30
- -1 cyano, hydroxyl Chemical group 0.000 claims description 29
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 28
- 125000004429 atoms Chemical group 0.000 claims description 14
- 125000005466 alkylenyl group Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 8
- YPHQUSNPXDGUHL-UHFFFAOYSA-N N-methylprop-2-enamide Chemical compound CNC(=O)C=C YPHQUSNPXDGUHL-UHFFFAOYSA-N 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 230000001404 mediated Effects 0.000 claims description 6
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 6
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 2
- YLXWLGWXHPGIMD-GOSISDBHSA-N C(C=C)(=O)N1C[C@@H](CCC1)COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C Chemical compound C(C=C)(=O)N1C[C@@H](CCC1)COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C YLXWLGWXHPGIMD-GOSISDBHSA-N 0.000 claims description 2
- VNHKOUCVWYOOAC-IBGZPJMESA-N C(C=C)(=O)N1[C@@H](CC1)COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C Chemical compound C(C=C)(=O)N1[C@@H](CC1)COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C VNHKOUCVWYOOAC-IBGZPJMESA-N 0.000 claims description 2
- VNHKOUCVWYOOAC-LJQANCHMSA-N C(C=C)(=O)N1[C@H](CC1)COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C Chemical compound C(C=C)(=O)N1[C@H](CC1)COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C VNHKOUCVWYOOAC-LJQANCHMSA-N 0.000 claims description 2
- DTUJVUIDYMFIAW-AWEZNQCLSA-N C(C=C)(=O)N[C@H](COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C)C Chemical compound C(C=C)(=O)N[C@H](COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C)C DTUJVUIDYMFIAW-AWEZNQCLSA-N 0.000 claims description 2
- CLFDGAFGHVOAPE-ONEGZZNKSA-N C1N(C(=O)/C=C/C)CC1Oc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C Chemical compound C1N(C(=O)/C=C/C)CC1Oc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C CLFDGAFGHVOAPE-ONEGZZNKSA-N 0.000 claims description 2
- ZFUQKYYJMUPMTI-UHFFFAOYSA-N CN(CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C)C(=O)C1CO1 Chemical compound CN(CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C)C(=O)C1CO1 ZFUQKYYJMUPMTI-UHFFFAOYSA-N 0.000 claims description 2
- ROYGBUGGEVOCCJ-UHFFFAOYSA-N CN(CCOc1c(N)ncnc1-c1cccc(c1)-n1ccc2cc(cc(F)c2c1=O)C1CC1)C(=O)C=C Chemical compound CN(CCOc1c(N)ncnc1-c1cccc(c1)-n1ccc2cc(cc(F)c2c1=O)C1CC1)C(=O)C=C ROYGBUGGEVOCCJ-UHFFFAOYSA-N 0.000 claims description 2
- LBPYBURZJMWWDQ-SNAWJCMRSA-N COC\C=C\C(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C Chemical compound COC\C=C\C(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C LBPYBURZJMWWDQ-SNAWJCMRSA-N 0.000 claims description 2
- HMNGHDQWQAJIPP-XZOQPEGZSA-N CO[C@@H]1C[C@@H](COc2c(N)ncnc2-c2cc(F)cc(N3CCc4cc(ccc4C3=O)C3CC3)c2CO)N(C1)C(=O)C=C Chemical compound CO[C@@H]1C[C@@H](COc2c(N)ncnc2-c2cc(F)cc(N3CCc4cc(ccc4C3=O)C3CC3)c2CO)N(C1)C(=O)C=C HMNGHDQWQAJIPP-XZOQPEGZSA-N 0.000 claims description 2
- NOBVNQWDJSXGNG-LEWJYISDSA-N CO[C@@H]1C[C@@H](COc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(cc3F)C3CC3)c2C)N(C1)C(=O)C=C Chemical compound CO[C@@H]1C[C@@H](COc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(cc3F)C3CC3)c2C)N(C1)C(=O)C=C NOBVNQWDJSXGNG-LEWJYISDSA-N 0.000 claims description 2
- MRMUBBWFULSDKQ-RPBOFIJWSA-N CO[C@H]1CCN([C@@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C)C(=O)C=C Chemical compound CO[C@H]1CCN([C@@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C)C(=O)C=C MRMUBBWFULSDKQ-RPBOFIJWSA-N 0.000 claims description 2
- NOBVNQWDJSXGNG-SFTDATJTSA-N CO[C@H]1C[C@@H](COc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(cc3F)C3CC3)c2C)N(C1)C(=O)C=C Chemical compound CO[C@H]1C[C@@H](COc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(cc3F)C3CC3)c2C)N(C1)C(=O)C=C NOBVNQWDJSXGNG-SFTDATJTSA-N 0.000 claims description 2
- MAEVSXHQLPMRFL-SNAWJCMRSA-N C\C=C\C(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C Chemical compound C\C=C\C(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C MAEVSXHQLPMRFL-SNAWJCMRSA-N 0.000 claims description 2
- OSLWRSOLKHYZCC-UHFFFAOYSA-N Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC1CN(C1)C(=O)C=C Chemical compound Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC1CN(C1)C(=O)C=C OSLWRSOLKHYZCC-UHFFFAOYSA-N 0.000 claims description 2
- YYRLWYMBOAJKGR-UHFFFAOYSA-N Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OCC1(CC1)NC(=O)C=C Chemical compound Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OCC1(CC1)NC(=O)C=C YYRLWYMBOAJKGR-UHFFFAOYSA-N 0.000 claims description 2
- MYNSOSQDEAAOFJ-UXHICEINSA-N Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC[C@@H]1C[C@@H](F)CN1C(=O)C=C Chemical compound Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC[C@@H]1C[C@@H](F)CN1C(=O)C=C MYNSOSQDEAAOFJ-UXHICEINSA-N 0.000 claims description 2
- ZVHBHHORKZBNIT-UWJYYQICSA-N Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC[C@@H]1C[C@H](CN1C(=O)C=C)C#N Chemical compound Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC[C@@H]1C[C@H](CN1C(=O)C=C)C#N ZVHBHHORKZBNIT-UWJYYQICSA-N 0.000 claims description 2
- QTZCKDFHDJVFRD-UHFFFAOYSA-N N-(2-fluoroethyl)prop-2-enamide Chemical compound FCCNC(=O)C=C QTZCKDFHDJVFRD-UHFFFAOYSA-N 0.000 claims description 2
- ZJMZNFQDSWTHLP-FQEVSTJZSA-N N-[3-[6-amino-5-[[(2S)-1-prop-2-enoylpyrrolidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound C1=C(F)C=C(C=2C(=C(N)N=CN=2)OC[C@H]2N(CCC2)C(=O)C=C)C(C)=C1NC(=O)C(C(=C1)F)=CC=C1C1CC1 ZJMZNFQDSWTHLP-FQEVSTJZSA-N 0.000 claims description 2
- SWPMNMYLORDLJE-UHFFFAOYSA-N N-ethylprop-2-enamide Chemical compound CCNC(=O)C=C SWPMNMYLORDLJE-UHFFFAOYSA-N 0.000 claims description 2
- WWPRHRSBBBVQRE-HNNXBMFYSA-N NC1=C(C(=NC=N1)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C)OC[C@H](C)NC(C#CC)=O Chemical compound NC1=C(C(=NC=N1)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C)OC[C@H](C)NC(C#CC)=O WWPRHRSBBBVQRE-HNNXBMFYSA-N 0.000 claims description 2
- JJMARAVUCXEXPI-QFIPXVFZSA-N Nc1ncnc(c1OC[C@@H]1CCCN1C(=O)C=C)-c1cc(F)cc(N2CCc3cc(ccc3C2=O)C2CC2)c1CO Chemical compound Nc1ncnc(c1OC[C@@H]1CCCN1C(=O)C=C)-c1cc(F)cc(N2CCc3cc(ccc3C2=O)C2CC2)c1CO JJMARAVUCXEXPI-QFIPXVFZSA-N 0.000 claims description 2
- NUJVYNDJMXNZNK-NRFANRHFSA-N Nc1ncnc(c1OC[C@@H]1CCN1C(=O)C=C)-c1cc(F)cc(N2CCc3cc(ccc3C2=O)C2CC2)c1CO Chemical compound Nc1ncnc(c1OC[C@@H]1CCN1C(=O)C=C)-c1cc(F)cc(N2CCc3cc(ccc3C2=O)C2CC2)c1CO NUJVYNDJMXNZNK-NRFANRHFSA-N 0.000 claims description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000051 modifying Effects 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 27
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- ZVHBHHORKZBNIT-UTKZUKDTSA-N Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC[C@@H]1C[C@@H](CN1C(=O)C=C)C#N Chemical compound Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC[C@@H]1C[C@@H](CN1C(=O)C=C)C#N ZVHBHHORKZBNIT-UTKZUKDTSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13195081 | 2013-11-29 | ||
EP13195081.8 | 2013-11-29 | ||
PCT/IB2014/066422 WO2015079417A1 (en) | 2013-11-29 | 2014-11-28 | Novel amino pyrimidine derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018094772A Division JP6667573B2 (ja) | 2013-11-29 | 2018-05-16 | 新規なアミノピリミジン誘導体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016538313A JP2016538313A (ja) | 2016-12-08 |
JP2016538313A5 true JP2016538313A5 (pt-PT) | 2017-10-26 |
JP6342495B2 JP6342495B2 (ja) | 2018-06-13 |
Family
ID=49674216
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016535053A Active JP6342495B2 (ja) | 2013-11-29 | 2014-11-28 | 新規なアミノピリミジン誘導体 |
JP2018094772A Active JP6667573B2 (ja) | 2013-11-29 | 2018-05-16 | 新規なアミノピリミジン誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018094772A Active JP6667573B2 (ja) | 2013-11-29 | 2018-05-16 | 新規なアミノピリミジン誘導体 |
Country Status (43)
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
DK3129470T3 (da) | 2014-04-07 | 2021-07-05 | Novartis Ag | Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗bcmaキメラ抗原受容体を使用した癌の処置 |
BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | GFRα−4キメラ抗原受容体を用いる癌の治療 |
SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
PL3194443T3 (pl) | 2014-09-17 | 2022-01-31 | Novartis Ag | Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
WO2016164580A1 (en) * | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
HUE059218T2 (hu) | 2015-04-08 | 2022-11-28 | Novartis Ag | CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel |
PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
CN109069597A (zh) | 2015-12-22 | 2018-12-21 | 诺华股份有限公司 | 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗 |
JP2019513347A (ja) | 2016-03-04 | 2019-05-30 | ノバルティス アーゲー | 複数のキメラ抗原受容体(car)分子を発現する細胞およびその使用 |
US11365252B2 (en) | 2016-07-20 | 2022-06-21 | University Of Utah Research Foundation | CD229 CAR T cells and methods of use thereof |
TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
KR20190104528A (ko) | 2016-12-03 | 2019-09-10 | 주노 쎄러퓨티크스 인코퍼레이티드 | Car-t 세포들 투여를 결정하는 방법 |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
CN111050545A (zh) | 2017-06-29 | 2020-04-21 | 朱诺治疗学股份有限公司 | 评估与免疫疗法相关的毒性的小鼠模型 |
SG11202003501XA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
CN111902159A (zh) | 2017-11-01 | 2020-11-06 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原(bcma)具有特异性的嵌合抗原受体 |
AR113796A1 (es) * | 2017-11-06 | 2020-06-10 | Lilly Co Eli | Compuestos inhibidores de tirosina cinasa de bruton (btk) |
WO2019109053A1 (en) | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
CN108069911A (zh) * | 2017-12-14 | 2018-05-25 | 中国药科大学 | 6-氨基-2-苯基嘧啶类化合物、制备方法和医药用途 |
US12006356B2 (en) | 2017-12-15 | 2024-06-11 | Juno Therapeutics, Inc. | Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
EP3806962A1 (en) | 2018-06-13 | 2021-04-21 | Novartis AG | Bcma chimeric antigen receptors and uses thereof |
MA53388A (fr) | 2018-07-25 | 2021-06-02 | Novartis Ag | Inhibiteurs d'inflammasome nlrp3 |
MX2021005024A (es) | 2018-11-01 | 2021-07-21 | Juno Therapeutics Inc | Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b. |
TW202021981A (zh) | 2018-11-01 | 2020-06-16 | 美商奇諾治療有限公司 | G蛋白偶合受體c類第5群成員d(gprc5d)特異性嵌合抗原受體 |
US20220008465A1 (en) | 2018-11-16 | 2022-01-13 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
PT3886875T (pt) | 2018-11-30 | 2024-06-27 | Juno Therapeutics Inc | Métodos para tratamento utilizando terapia celular adotiva |
US20220096651A1 (en) | 2019-01-29 | 2022-03-31 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
JP2022534216A (ja) | 2019-05-23 | 2022-07-28 | ノバルティス アーゲー | Btk阻害剤の結晶形態 |
WO2020234780A1 (en) | 2019-05-23 | 2020-11-26 | Novartis Ag | Methods of treating asthma using a bruton's tyrosine kinase inhibitor |
BR112021022602A2 (pt) * | 2019-05-23 | 2022-01-04 | Novartis Ag | Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton |
KR20220011652A (ko) * | 2019-05-23 | 2022-01-28 | 노파르티스 아게 | 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법 |
EP4081514A1 (en) * | 2019-12-23 | 2022-11-02 | Biogen MA Inc. | Btk inhibitors |
CN115916223A (zh) | 2020-04-10 | 2023-04-04 | 朱诺治疗学股份有限公司 | 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途 |
US11708366B2 (en) | 2020-08-14 | 2023-07-25 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
CN116209444A (zh) * | 2020-08-14 | 2023-06-02 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物的晶型及其制备方法 |
KR20230134560A (ko) * | 2021-01-26 | 2023-09-21 | 노파르티스 아게 | 약학적 조성물 |
EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
EP4395779A1 (en) | 2021-09-03 | 2024-07-10 | Novartis AG | Lou064 for treating multiple sclerosis |
TW202322820A (zh) | 2021-12-14 | 2023-06-16 | 瑞士商諾華公司 | 使用lou064之治療方法 |
TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用lou064治療化膿性汗腺炎之方法 |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
US20240041929A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
TW202415644A (zh) | 2022-09-30 | 2024-04-16 | 瑞士商諾華公司 | 合成方法及中間體 |
WO2024129778A2 (en) | 2022-12-13 | 2024-06-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof |
CN117024354B (zh) * | 2023-10-08 | 2023-12-08 | 天津凯莱英制药有限公司 | 瑞米布替尼的制备方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
CA2426508A1 (en) | 2000-10-23 | 2002-05-16 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states |
MXPA03004037A (es) | 2000-11-07 | 2003-08-19 | Novartis Ag | Derivados de indolilmaleimida como inhibidores de proteina de cinasa c. |
AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
HUP0500844A2 (en) | 2002-12-09 | 2007-08-28 | Univ Texas | Methods for selectively inhibiting janus tyrosine kinase 3(jak3) |
EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
CA2524048C (en) | 2003-05-19 | 2013-06-25 | Irm Llc | Immunosuppressant compounds and compositions |
MXPA06007640A (es) | 2004-01-12 | 2007-04-17 | Cytopia Res Pty Ltd | Inhibidores de quinasa selectivos. |
MX2007011041A (es) | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. |
AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
JP2010502751A (ja) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ,インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
EP2532235A1 (en) | 2006-09-22 | 2012-12-12 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
KR101791981B1 (ko) | 2007-03-14 | 2017-11-01 | 비온실 에스.알.엘. | 화학요법 약물-내성 상피성 종양을 치료하기 위한 siRNA-매개 유전자 침묵화 |
WO2009137596A1 (en) | 2008-05-06 | 2009-11-12 | Cgi Pharmaceuticals, Inc. | Substituted amides, method of making, and use as btk inhibitors |
KR101523451B1 (ko) | 2008-07-02 | 2015-05-27 | 에프. 호프만-라 로슈 아게 | 키나아제 억제제로서의 신규 페닐피라지논 |
EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
US20100261776A1 (en) | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
SG175287A1 (en) | 2009-04-24 | 2011-11-28 | Hoffmann La Roche | Inhibitors of bruton's tyrosine kinase |
AR080328A1 (es) * | 2010-02-26 | 2012-03-28 | Boehringer Ingelheim Int | Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros |
UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
US8703767B2 (en) | 2011-04-01 | 2014-04-22 | University Of Utah Research Foundation | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors |
EP2710007B1 (en) | 2011-05-17 | 2019-12-11 | The Regents of The University of California | Kinase inhibitors |
SG10201604682VA (en) | 2011-06-10 | 2016-07-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
WO2013003629A2 (en) | 2011-06-28 | 2013-01-03 | Pharmacyclics, Inc. | Methods and compositions for inhibition of bone resorption |
CA2841111A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
US9273317B2 (en) | 2011-08-09 | 2016-03-01 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of MYC-driven tumor cells |
KR102054468B1 (ko) | 2011-10-19 | 2019-12-11 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(btk)의 억제제의 용도 |
CA2853498A1 (en) | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
CN103998447A (zh) | 2011-12-09 | 2014-08-20 | 弗·哈夫曼-拉罗切有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
JPWO2013133367A1 (ja) | 2012-03-09 | 2015-07-30 | カルナバイオサイエンス株式会社 | 新規トリアジン誘導体 |
WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
EP2838898B1 (en) | 2012-04-20 | 2017-01-18 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
WO2013173518A1 (en) | 2012-05-16 | 2013-11-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CA2881519A1 (en) | 2012-08-10 | 2014-02-13 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
CA2887435A1 (en) | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
US9512084B2 (en) * | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
-
2014
- 2014-11-13 US US14/540,140 patent/US9512084B2/en active Active
- 2014-11-27 JO JOP/2014/0341A patent/JO3314B1/ar active
- 2014-11-27 UY UY0001035858A patent/UY35858A/es active IP Right Grant
- 2014-11-27 AR ARP140104439A patent/AR098549A1/es active IP Right Grant
- 2014-11-28 AP AP2016009158A patent/AP2016009158A0/en unknown
- 2014-11-28 HU HUE20158961A patent/HUE062248T2/hu unknown
- 2014-11-28 TW TW103141506A patent/TWI652261B/zh active
- 2014-11-28 ES ES17191467T patent/ES2791525T3/es active Active
- 2014-11-28 LT LTEP17191467.4T patent/LT3299368T/lt unknown
- 2014-11-28 PE PE2016000683A patent/PE20160869A1/es unknown
- 2014-11-28 PT PT201589611T patent/PT3689865T/pt unknown
- 2014-11-28 CN CN201480058515.5A patent/CN105683181B/zh active Active
- 2014-11-28 MY MYPI2016701223A patent/MY179059A/en unknown
- 2014-11-28 NO NO14821285A patent/NO3074386T3/no unknown
- 2014-11-28 MX MX2016006908A patent/MX367911B/es active IP Right Grant
- 2014-11-28 KR KR1020167013830A patent/KR102380539B1/ko active IP Right Grant
- 2014-11-28 SI SI201431570T patent/SI3299368T1/sl unknown
- 2014-11-28 RS RS20230437A patent/RS64275B1/sr unknown
- 2014-11-28 BR BR112016010397-1A patent/BR112016010397B1/pt active IP Right Grant
- 2014-11-28 UA UAA201603623A patent/UA117256C2/uk unknown
- 2014-11-28 MA MA39055A patent/MA39055B1/fr unknown
- 2014-11-28 EP EP23161775.4A patent/EP4219478A1/en active Pending
- 2014-11-28 HR HRP20230585TT patent/HRP20230585T1/hr unknown
- 2014-11-28 MY MYPI2020002915A patent/MY191381A/en unknown
- 2014-11-28 EP EP14821285.5A patent/EP3074386B1/en active Active
- 2014-11-28 FI FIEP20158961.1T patent/FI3689865T3/fi active
- 2014-11-28 EP EP17191467.4A patent/EP3299368B1/en active Active
- 2014-11-28 PL PL17191467T patent/PL3299368T3/pl unknown
- 2014-11-28 ES ES20158961T patent/ES2947770T3/es active Active
- 2014-11-28 PT PT148212855T patent/PT3074386T/pt unknown
- 2014-11-28 ES ES14821285.5T patent/ES2655527T3/es active Active
- 2014-11-28 SI SI201430536T patent/SI3074386T1/en unknown
- 2014-11-28 JP JP2016535053A patent/JP6342495B2/ja active Active
- 2014-11-28 SI SI201432031T patent/SI3689865T1/sl unknown
- 2014-11-28 HU HUE17191467A patent/HUE049794T2/hu unknown
- 2014-11-28 EA EA201691125A patent/EA031218B1/ru not_active IP Right Cessation
- 2014-11-28 LT LTEP20158961.1T patent/LT3689865T/lt unknown
- 2014-11-28 KR KR1020227009823A patent/KR102421388B1/ko active IP Right Grant
- 2014-11-28 PL PL14821285T patent/PL3074386T3/pl unknown
- 2014-11-28 EP EP20158961.1A patent/EP3689865B1/en active Active
- 2014-11-28 PL PL20158961.1T patent/PL3689865T3/pl unknown
- 2014-11-28 LT LTEP14821285.5T patent/LT3074386T/lt unknown
- 2014-11-28 DK DK17191467.4T patent/DK3299368T3/da active
- 2014-11-28 NZ NZ718835A patent/NZ718835A/en unknown
- 2014-11-28 CU CU2016000078A patent/CU24384B1/es unknown
- 2014-11-28 HU HUE14821285A patent/HUE037588T2/hu unknown
- 2014-11-28 DK DK14821285.5T patent/DK3074386T3/en active
- 2014-11-28 WO PCT/IB2014/066422 patent/WO2015079417A1/en active Application Filing
- 2014-11-28 CA CA2926908A patent/CA2926908C/en active Active
- 2014-11-28 PT PT171914674T patent/PT3299368T/pt unknown
- 2014-11-28 AU AU2014356069A patent/AU2014356069B2/en active Active
- 2014-11-28 RS RS20200550A patent/RS60251B1/sr unknown
- 2014-11-28 DK DK20158961.1T patent/DK3689865T3/da active
- 2014-11-28 TN TN2016000128A patent/TN2016000128A1/en unknown
- 2014-11-28 CN CN201910288376.XA patent/CN110172056B/zh active Active
- 2014-11-28 RS RS20171206A patent/RS56657B1/sr unknown
-
2016
- 2016-04-05 ZA ZA2016/02275A patent/ZA201602275B/en unknown
- 2016-04-06 IL IL244943A patent/IL244943B/en active IP Right Grant
- 2016-04-21 US US15/135,296 patent/US20160235746A1/en not_active Abandoned
- 2016-04-28 PH PH12016500791A patent/PH12016500791A1/en unknown
- 2016-05-03 CL CL2016001055A patent/CL2016001055A1/es unknown
- 2016-05-27 CR CR20160244A patent/CR20160244A/es unknown
- 2016-05-27 SV SV2016005206A patent/SV2016005206A/es unknown
- 2016-06-20 EC ECIEPI201654826A patent/ECSP16054826A/es unknown
- 2016-10-06 HK HK16111636.9A patent/HK1223368A1/zh unknown
-
2017
- 2017-12-22 CY CY20171101345T patent/CY1119705T1/el unknown
- 2017-12-27 HR HRP20171999TT patent/HRP20171999T1/hr unknown
-
2018
- 2018-05-08 US US15/974,190 patent/US10457647B2/en active Active
- 2018-05-16 JP JP2018094772A patent/JP6667573B2/ja active Active
- 2018-09-10 HK HK18111597.4A patent/HK1252317A1/zh unknown
-
2019
- 2019-09-16 US US16/571,405 patent/US11180460B2/en active Active
-
2020
- 2020-05-12 HR HRP20200775TT patent/HRP20200775T1/hr unknown
- 2020-05-25 CY CY20201100478T patent/CY1122924T1/el unknown
-
2021
- 2021-10-22 US US17/508,054 patent/US11673868B2/en active Active
-
2023
- 2023-05-01 US US18/309,948 patent/US20230312483A1/en active Pending
- 2023-06-27 CY CY20231100301T patent/CY1126056T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016538313A5 (pt-PT) | ||
HRP20171999T1 (hr) | Novi derivati aminopirimidina | |
JP2014513110A5 (pt-PT) | ||
JP2015514808A5 (pt-PT) | ||
JP2019510796A5 (pt-PT) | ||
JP2017528487A5 (pt-PT) | ||
RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
JP2014530900A5 (pt-PT) | ||
RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
JP2016523974A5 (pt-PT) | ||
HRP20220990T1 (hr) | 3-supstituirane propionske kiseline kao inhibitori alfa v integrina | |
JP2016506960A5 (pt-PT) | ||
JP2016506962A5 (pt-PT) | ||
JP2014526549A5 (pt-PT) | ||
HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
JP2013512903A5 (pt-PT) | ||
JP2016517878A5 (pt-PT) | ||
JP2013528204A5 (pt-PT) | ||
RU2007116987A (ru) | Новые соединения | |
JP2009501745A5 (pt-PT) | ||
RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
JP2019505595A5 (pt-PT) | ||
JP2014508804A5 (pt-PT) |